Monalizumab treatment can restore CD107 and IFN-γ production in NK cells against various tumor cells, whereas the combination of monalizumab and anti-PD-L1 mAb (Durvalumab) showed additive effects, as demonstrated by rescue of the anti-tumor activity of both CD8+T and NK cells. Here, CD8A is linked to neoplasm.